Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Evolving Biosimilar Pathway Brings Mid-Review Policy Issues

Jul 15 2016

• By Sue Sutter

Related Content

Biosimilar Launch Notification Delay Remains In The US, Might Not Matter For Newer Products

Jul 07 2016

Biosimilar Naming: FDA Asked Celltrion For Two Kinds Of Suffixes

Jul 15 2016

With Inflectra, FDA Showed Flexibility On Biosimilar Pediatric Study Plans

Jul 15 2016

Inflectra Analytical Data Eased FDA's 'Residual Uncertainty' About Remicade Differences

Jul 15 2016

Inflectra Label Not Exactly Silent On Remicade's Orphan-Protected Claim

Apr 06 2016

Biosimilar Template Revisited: Inflectra Approval Binds And Separates From Remicade

Apr 06 2016

Biosimilar Labeling: FDA Says Leave Comparability Data Out

Mar 31 2016

Pfizer's Remicade Biosimilar: Sept. 15 Is Earliest Launch Date

Jun 08 2016

Related Companies

Celltrion, Inc.

Johnson & Johnson

Novartis AG

Amgen, Inc.

Parexel International Corp.

Pfizer Inc.

Additional Topics

United States Approvals Drug Review Biosimilars BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window